Awareness and behaviour of European physicians in relation to microalbuminuria and organ damage: An ESH-endorsed survey

Journal of Hypertension

Volumn 28, Issue 11, 2010, Pages 2204-2209

  Haller, Hermann ^a   Menne, Jan ^a   Mancia, Giuseppe ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

albuminuria; cardiovascular risk; diabetes; hypertension; microalbuminuria; renal function

Indexed keywords

CREATININE;

ARTICLE; AWARENESS; CARDIOLOGIST; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CREATININE BLOOD LEVEL; DISEASE COURSE; FRANCE; GLOMERULUS FILTRATION RATE; HEALTH SURVEY; HEART INJURY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTERVIEW; ITALY; KIDNEY FUNCTION; KIDNEY INJURY; MEDICAL SOCIETY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; RISK FACTOR; SPAIN; STANDARDIZATION; UNITED KINGDOM; URINALYSIS;

EID: 77958515304     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833cfd40     Document Type: Article

References (24)

1. O'Keefe JH, Carter MD, Lavie CJ. Primary and secondary prevention of cardiovascular diseases: a practical evidence based approach. Mayo Clin Proc 2009; 84:741-757.
2. World Health Organization. Cardiovascular diseases, Factsheet No317. 2007. (http://www.who.int/mediacentre/factsheets/fs317/en/index.html). Version current at 18th September 2009.
3. Chugh A, Bakris GL. Microalbuminuria: what is it? Why is it important? What should be done about it? An update. J Clin Hypertension 2007; 9:196-200.
4. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310:356-360.
5. Weir MR. Microalbuminuria in type 2 diabetes: an important overlooked cardiovascular risk factor. J Clin Hypertens 2004; 6:134-143.
6. Asselbergs FW, Hillege HL, van Gilst WH. Framingham score and microalbuminuria: combined future targets for primary prevention? Kidney Int 2004; 92:S111-S114.
7. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in the general population. Circulation 2002; 106:1777-1782.
8. Asselbergs FW, DiercksGF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110:2809-2816.
9. Ibsen H, Olsen MH, Machtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45:198-202. (Pubitemid 40179960)
10. Redon J, Pascual JM. What is the evolution of albuminuria in treated patients? In Ruilope LM, editor. Microalbuminuria: the importance of treatment and prevention. Sankyo Co., Ltd.; 2006; 81-89.
11. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improve Global Outcomes (KDIGO). Kidney Int 2005; 67:2089-2100.
12. The American Diabetes Association. Standards of medical care in diabetes: 2009. Diabetes Care 2009; 32(Suppl 1):S13-S61.
13. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guidelines for the management of Arterial Hypertension: The Task force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
14. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. J Am Med Assoc 2003; 289:2560-2572.
15. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009; 32:3-107.
16. Basi S, Lewis JB. Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am J Kidney Dis 2006; 47:927-946.
17. Verhave JC, Gansevoort RT, Hillege HL, Bakker SJ, De Zeeuw D, de Jong PE. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int 2004; 66 (Suppl 92):S18-S21.
18. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, Wareham NJ, European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol 2004; 33:189-198.
19. Ninomiva T, Perkovic V, Verdon C, Barzi F, Cass A, Gallagher M, et al. Proteinuria and stroke: a meta-analysis of cohort studies. Am J Kidney Dis 2009; 53:417-425.
20. Tebbe U, Bramlage P, Thoenes M, Paar WD, Danchin N, Volpe M, et al. Prevalence of microalbuminuria and its associated cardiovascular risk: German and Swiss results of the recent global i-SEARCH survey. Swiss Med Wkly 2009; 139:473-480.
21. Gaspari F, Perico N, Remuzzi G. Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis 2006; 47:1-7.
22. Volpe M. Microalbuminuria screening in patients with hypertension: recommendations for clinical practice. Int J Clin Pract 2008; 62:97-108.
23. Ewald B, Attia J. Which test to detect microalbuminuria in diabetic patients? A systematic review. Aust Fam Physician 2004; 33:565-567; 571.
24. Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort RT. Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 2008; 168:897-905.